METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for Hard-to-Treat prostate cancer
Disease control CompletedThis study tested a new oral drug (CPI-1205) combined with standard hormone-blocking treatments (enzalutamide or abiraterone/prednisone) in 175 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to find the safest dose and see if the combination works …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Finnish prostate cancer study reveals treatment patterns and outcomes
Knowledge-focused CompletedThis study looked at over 1,000 men in Finland with metastatic prostate cancer to understand their health, treatments, and how the disease progresses. Researchers collected information from medical records to see what treatments were used and how well they worked. The goal was to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC